Anti-Inflammatory Therapeutic

OCR Number: OCR 6426

Description:

Inflammasome–mediated inflammatory disease treatment with β-hydroxybutyrate and similar compounds

- NLRP3 inflammasome activation is implicated in a number of diseases such as gout, atherosclerosis, type-2 diabetes, Alzheimer's disease, multiple sclerosis, Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS).
- The ketone body β-hydroxybutyrate (BHB) as well as γ-hydroxybutyric acid (GHB) can inhibit NLRP3 inflammasome activation. BHB delivery in vivo reduced NLRP3 inflammasome-mediated Interleukin (IL)-1β secretion, reversing phenotypes in animal models with gout, MWS, FCAS, and peritonitis.
- Intellectual property – A provisional patent application has been filed

PI: Vishwa Dixit

Licensing Contact: Hong Peng
hong.peng@yale.edu

Reduction of neurotrophil infiltration as well as NLRP3 inflammasome and related cytokines in the ketogenic diet fed mouse model.